Skip to content
Companies

Strand Therapeutics

Programmable mRNA therapies for solid tumors

Raised to date

$108.1M

of $120.1M offered across 1 Form D filing

Still open
$12M
Investors
10
Last filed
Mar 17, 2026

About

Strand Therapeutics is a clinical-stage biotechnology company developing programmable mRNA therapeutics to treat cancer and other life-threatening diseases. Founded by biological engineers from MIT, the company aims to create autonomous medicines that can precisely target diseased cells and deliver multi-functional treatments. The core technology is based on the first mRNA programming language, designed to improve therapeutic outcomes.

The company's innovation lies in its intelligent, tumor-targeted mRNA platform that enables the creation of programmable drugs. These drugs can act specifically at the site of disease, which could offer a more precise and effective alternative to systemic treatments.

Funding

  • EquityFiled Mar 17, 2026Form D
    $108.1M/ $120.1M

Product

STX-001

Cancer Immunotherapy

STX-001 is a programmable mRNA therapy candidate designed for the treatment of solid tumors. It utilizes a multi-modal synthetic self-replicating mRNA technology to deliver a prolonged and locally-acting IL-12 cytokine directly into the tumor microenvironment. The therapy has received Investigational New Drug (IND) clearance from the FDA and is currently in Phase 1 clinical trials.

  • Programmable, self-replicating mRNA technology
  • Localized delivery of IL-12 cytokine
  • Targeting of the tumor microenvironment

Built for

The primary customers are patients with solid tumors who may not be responding adequately to current immunotherapies. The company's broader focus also includes patients with various autoimmune diseases.

People on file